Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Introduction.: A KRAS mutation represented the first genomic biomarker to predict lack of benefit from anti-epidermal growth factor receptor (EGFR) antibody therapy in advanced colorectal cancer (CRC). Expanded RAS testing has further refined the treatment approach, but understanding of genomic alterations underlying primary and acquired resistance is limited and further study is needed. Materials and Methods.: We prospectively analyzed 4,422 clinical samples from patients with advanced CRC, using hybrid-capture based comprehensive genomic profiling (CGP) at the request of the individual treating physicians. Comparison with prior molecular testing results, when available, was performed to assess concordance. Results.: We identified a RAS/RAF pathway mutation or amplification in 62% of cases, including samples harboring KRAS mutations outside of the codon 12/13 hotspot region in 6.4% of cases. Among cases with KRAS non-codon 12/13 alterations for which prior test results were available, 79 of 90 (88%) were not identified by focused testing. Of 1,644 RAS/RAF wild-type cases analyzed by CGP, 31% harbored a genomic alteration (GA) associated with resistance to anti-EGFR therapy in advanced CRC including mutations in PIK3CA, PTEN, EGFR, and ERBB2. We also identified other targetable GA, including novel kinase fusions, receptor tyrosine kinase amplification, activating point mutations, as well as microsatellite instability. Conclusion.: Extended genomic profiling reliably detects alterations associated with lack of benefit to anti-EGFR therapy in advanced CRC, while simultaneously identifying alterations potentially important in guiding treatment. The use of CGP during the course of clinical care allows for the refined selection of appropriate targeted therapies and clinical trials, increasing the chance of clinical benefit and avoiding therapeutic futility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, mutations in KRAS, BRAF, and PTN can lead to resistance to certain targeted treatments, including EGFR therapies [86].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Research works printed but not linked: 1
- NCCN Guidelines v.3.2015
Cited by
Milbury, C. A., Creeden, J., Yip, W.-K., Smith, D. L., Pattani, V., Maxwell, K., Sawchyn, B., Gjoerup, O., Meng, W., Skoletsky, J., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264138 · Cited by 376
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
Amatu, A., Sartore-Bianchi, A., Bencardino, K., Pizzutilo, E. G., Tosi, F., & Siena, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz383 · Cited by 309
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Pietrantonio, F., Di Nicolantonio, F., Schrock, A. B., Lee, J., Tejpar, S., Sartore-Bianchi, A., Hechtman, J. F., Christiansen, J., Novara, L., Tebbutt, N., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx089 · Cited by 317
Self-citationGenomic Profiling of Small-Bowel Adenocarcinoma
Schrock, A. B., Devoe, C. E., McWilliams, R., Sun, J., Aparicio, T., Stephens, P. J., Ross, J. S., Wilson, R., Miller, V. A., Ali, S. M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1051 · Cited by 227
Self-citationRoss, J. S., Fakih, M., Ali, S. M., Elvin, J. A., Schrock, A. B., Suh, J., Vergilio, J., Ramkissoon, S., Severson, E., Daniel, S., et al. (2018) · Cancer · doi:10.1002/cncr.31125 · Cited by 210
Self-citationUpdate on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 121
Bray, S. M., Lee, J., Kim, S. T., Hur, J. Y., Ebert, P. J., Calley, J. N., Wulur, I. H., Gopalappa, T., Wong, S. S., Qian, H.-R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51981-5 · Cited by 82
Self-citationBhatia, S., Monkman, J. H., Toh, A. K. L., Nagaraj, S. H., & Thompson, E. W. (2017) · Biochemical Journal · doi:10.1042/bcj20160782 · Cited by 79
Schrock, A. B., Pavlick, D., Klempner, S. J., Chung, J. H., Forcier, B., Welsh, A., Young, L., Leyland-Jones, B., Bordoni, R., Carvajal, R. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3103 · Cited by 71
Self-citationPrognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer
Martelli, V., Pastorino, A., & Sobrero, A. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108239 · Cited by 73
Wang, G., He, Y., Sun, Y., Wang, W., Qian, X., Yu, X., & Pan, Y. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02213-9 · Cited by 47
Johnson, B., Loree, J. M., Jacome, A. A. D. A., Mendis, S. R., Syed, M., Morris, V. K., Parseghian, C. M., Dasari, A. N., Pant, S., Raymond, V. M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00102 · Cited by 44
Chawla, A., Jankú, F., Wheler, J. J., Miller, V. A., Ryan, J., Anhorn, R., Zhou, Z., & Signorovitch, J. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00074 · Cited by 44
Self-citationLi, G., Pavlick, D. C., Chung, J., Bauer, T. M., Tan, B. A., Peguero, J., Ward, P. J., Kallab, A. M., Bufill, J. A., Hoffman, A. D., et al. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.05.05 · Cited by 38
Self-citationClifton, K., Rich, T. A., Parseghian, C., Raymond, V. M., Dasari, A., Pereira, A. A. L., Willis, J., Loree, J. M., Bauer, T. M., Chae, Y. K., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00141 · Cited by 37
Self-citationMei, Y., Bi, W. L., Agolia, J. P., Hu, C., Giantini-Larsen, A., Meredith, D. M., Abdulmohsen, S. A., Bale, T., Dunn, G. P., Abedalthagafi, M., et al. (2021) · Pituitary · doi:10.1007/s11102-020-01114-3 · Cited by 34
Voutsadakis, I. A. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103987 · Cited by 31
Wang, N., Cao, Y., Si, C., Shao, P., Su, G., Wang, X., Bao, J., & Liu, Y. (2022) · Cancers · doi:10.3390/cancers14205160 · Cited by 32
Emerging actionable targets to treat therapy-resistant colorectal cancers
Grassilli, E., & Cerrito, M. G. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.96 · Cited by 33
Huang, K.-B., Liu, R., Peng, Q.-H., Li, Z.-S., Jiang, L.-J., Guo, S., Zhou, Q.-H., Liu, T.-Y., Deng, C.-Z., Yao, K., et al. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.10.016 · Cited by 23
Lai, A. Z., Schrock, A. B., Erlich, R., Ross, J. S., Miller, V. A., Yakirevich, E., Ali, S. M., & Braiteh, F. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0376 · Cited by 26
Self-citationColorectal cancer genomics and designing rational trials
Mondaca, S., & Yaeger, R. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.27 · Cited by 23
Lièvre, A., Ouine, B., Canet, J., Cartier, A., Amar, Y., Cacheux, W., Mariani, O., Guimbaud, R., Selves, J., Lecomte, T., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.353 · Cited by 18
Voutsadakis, I. A. (2023) · Current Oncology · doi:10.3390/curroncol30060397 · Cited by 14
Nagamine, A., Araki, T., Nagano, D., Miyazaki, M., & Yamamoto, K. (2019) · Oncology Letters · doi:10.3892/ol.2019.10075 · Cited by 12
Primary Epithelioid Sarcoma of Orbit: A Case Report and Review of the Literature
Kaya, E. A., Broadbent, T. J., Thomas, C. J., Wagner, A. E., Thatcher, S. H., Lamoreaux, W. T., Fairbanks, R. K., & Lee, C. M. (2018) · Case Reports in Oncological Medicine · doi:10.1155/2018/3989716 · Cited by 10
Martínez-Fernández, P., Pose, P., Gaitón, R. D., García, A., Trigo‐Sánchez, I., Rodríguez-Zarco, E., Garcia-Ruiz, M., Barba, I., Izquierdo-García, M., Valero-García, J., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050360 · Cited by 10
Voutsadakis, I. A. (2022) · Medicina · doi:10.3390/medicina58101498 · Cited by 12
Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants
Chen, S.-Y., Gu, J., Wu, K., Zhao, X., & Lu, Y. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0026 · Cited by 9
Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy
Fleitas, T., Martínez‐Ciarpaglini, C., Ayala, J., Gauna, C., Denis, R., Yoffe, I., Sforza, S., Martínez, M. T., Pomata, A., Ibarrola‐Villava, M., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2191 · Cited by 7
Proudman, D. G., DeVito, N. C., Belinson, S., Allo, M. A., Morris, E. D., Signorovitch, J., & Patel, A. K. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2080463 · Cited by 7
The Evolving Role of Genomics in Colorectal Cancer
Berner, A., & Murugaesu, N. (2024) · Clinical Oncology · doi:10.1016/j.clon.2024.10.033 · Cited by 6
Voutsadakis, I. A. (2025) · Pharmacogenomics · doi:10.1080/14622416.2025.2479414 · Cited by 4
Identification of Genomic Signatures for Colorectal Cancer Survival Using Exploratory Data Mining
Hummel, J. J., Liu, D., Tallon, E. M., Snyder, J., Warren, W. C., Shyu, C., Mitchem, J. B., & Cortese, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063220 · Cited by 3
Ozato, T., Kono, Y., Horiguchi, S., Tsutsumi, K., Yamamoto, H., Hirasawa, A., Ennishi, D., Tomida, S., Toyooka, S., & Otsuka, M. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115401 · Cited by 3
Emmett, M. J., Quintanilha, J. C. F., Graf, R. P., Li, G., Tukachinsky, H., Schrock, A. B., Morley, S., Fisher, V. A., Oxnard, G. R., Lieu, C. H., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100036 · Cited by 2
Self-citationLièvre, A., Ouine, B., Canet, J., Cartier, A., Amar, Y., Cacheux, W., Mariani, O., Guimbaud, R., Sèlves, J., Lecomte, T., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0130-x · Cited by 2
Stepanova, M., Kuznetsova, O. A., Shilo, P. S., Moiseenko, F. V., Abduloeva, N. K., Artemeva, E., Zhabina, A. S., Kramchaninov, M. M., Volkov, N. M., Покатаев, И. А., et al. (2022) · Surgery and Oncology · doi:10.17650/2686-9594-2022-12-3-26-35 · Cited by 1
Pharmacogenomics: Success and Challenges
Hussaini, M., & McLeod, H. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_38
EMT and MET: Underpinning the Phenotypic Plasticity and Chemoresistance in Breast Cancer
Bhatia, S. (2020) · Queensland University of Technology · doi:10.5204/thesis.eprints.180913
Molecular Classifications of Gastrointestinal Tract Tumors
Rastogi, A., Bihari, C., Patil, A. G., Majumdar, K., & Das, P. (2022) · Springer eBooks · doi:10.1007/978-981-16-6395-6_23 · Cited by 1
Ozato, T., Kono, Y., Horiguchi, S., Tsutsumi, K., Yamamoto, H., Hirasawa, A., Ennishi, D., Tomida, S., Toyooka, S., & Otsuka, M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5132243
小腸腺癌における相同組換え修復遺伝子変異のゲノムプロファイルと臨床的影響
Ozato, T. (2025) · Okayama University Scientific Achievement Repository (Okayama University) · doi:10.18926/69664
Rahman, N. L. A. (2023) · Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia)
Metadata
- Authors
- Rankin, A., Klempner, S. J., Erlich, R., Sun, J. X., Grothey, A., Fakih, M., George, T. J., Lee, J., Ross, J. S., Stephens, P. J., Miller, V. A., Ali, S. M., & Schrock, A. B.
- Affiliations
- Foundation Medicine (United States) (US)
- Angeles Clinic and Research Institute (US)
- Mayo Clinic (US)
- City Of Hope National Medical Center (US)
- University of Florida (US)
- Samsung Medical Center (KR)
- Corresponding author
- Schrock, Alexa B.
- ORCID
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09-28
- Volume
- 21
- Issue
- 11
- Pages
- 1306-1314
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC5189622
- OpenAlex
- W2527263072
- Cited by
- 40
- References
- 58
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 2 · 2022: 8 · 2021: 2 · 2019: 8 · 2018: 8 · 2017: 5
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- advanced colorectal cancer, anti-EGFR antibody therapy, KRAS mutation, acquired resistance, comprehensive genomic profiling, PIK3CA, PTEN, ERBB2, kinase fusions, microsatellite instability, targeted therapy selection, futility of treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.